PeptideInfo
العربيةGet the app
☰
MitochondrialNot approved (US)

Humanin

HN · Humanin-G (HNG)

Binding at the CNTFR/WSX-1/gp130 complex triggers JAK2/STAT3 signaling. Humanin directly inhibits neuronal apoptosis driven by Bax, interacts with IGF-1 receptors in insulin sensitization and suppresses NF-κB signaling associated with inflammation.

Not medical advice. Educational reference only.

Route
Subcutaneous injection
Storage
Keep at 2–8°C after mixing and use within 28 days.

What is Humanin?

Humanin is a mitochondrial peptide containing 21 amino acids. Its coding region lies within mitochondrial 16S rRNA. Discovery in 2001 came from a cDNA library prepared from brain tissue resistant to Alzheimer’s disease. Experimental findings include protection of neurons, suppression of programmed cell death and metabolic effects. Blood concentrations fall substantially with age. Investigations address Alzheimer’s disease, diabetes and protection of the cardiovascular system; use remains experimental.

Mechanism of action

Binding at the CNTFR/WSX-1/gp130 complex triggers JAK2/STAT3 signaling. Humanin directly inhibits neuronal apoptosis driven by Bax, interacts with IGF-1 receptors in insulin sensitization and suppresses NF-κB signaling associated with inflammation.

Targets: CNTFR/WSX-1/gp130 complex · Bax · IGF-1 receptor

Research indications

  • Energy Metabolism

    Effective

    Experimental findings suggest better mitochondrial energy handling and ATP generation.

  • Metabolic Health

    Effective

    Potential benefits involve greater insulin sensitivity and improved glucose handling.

  • Longevity Markers

    Moderate

    Preliminary findings suggest changes in markers associated with cellular aging.

Interactions

  • Medications

    Caution

    Consult your prescriber before combining this compound with any medication.

  • BPC-157

    Compatible

  • NAD+

    Compatible

  • Vitamin D

    Compatible

How to reconstitute and inject

Diluent: Use bacteriostatic water only; avoid saline because precipitation can occur.

  1. Let the refrigerated vial warm to room temperature for 15–20 minutes before preparing it.
  2. Disinfect the stopper using an alcohol swab, then wait until the surface has dried fully in the air.
  3. Use a sterile syringe to measure your calculated amount of bacteriostatic water. Use this diluent only; avoid saline because precipitation may occur.
  4. Introduce the water gradually against the inner glass wall. Keep the stream away from the peptide powder itself.
  5. Rotate the vial gently to mix its contents. Do not shake forcefully, because vigorous agitation can degrade the peptide.
  6. Wait 2–3 minutes for the powder to dissolve completely. Check that the liquid is transparent and has no color.
  7. Measure your calculated dose with an insulin syringe in preparation for administration beneath the skin.
  8. Use the abdomen, thigh or upper arm for subcutaneous administration. Change the injection location each time to help prevent lipodystrophy.
  9. Return the mixed vial to refrigeration at 2–8°C. Use the prepared solution within 28 days of mixing.

What to expect

Week 1–2
Early effects may accompany an adjustment period. Watch for any unwanted reaction as you adapt.
Week 2–4
The principal effects may begin emerging. Follow your clinician’s recommendations for any change in dose.
Week 4–8
Main effects are expected to be apparent at this stage. Review your progress together with your clinician.
Week 8+
Review the outcome with your clinician and decide whether to continue, take a cycle break or adjust the dose. These timings do not establish effectiveness for every compound.

Side effects and safety

  • Bruising, redness or mild soreness where the injection is given
  • Possible allergic response; stop use if you develop hives or a rash
  • Variable individual response; begin with the lowest dose and watch closely for reactions
  • Discuss use with your clinician beforehand and report symptoms that are unusual for you

Humanin: not approved in the US.

Regulatory status

  • US

    Not approved

    FDA — experimental use only, without therapeutic approval. The regulatory record indicates no prescription requirement, no 503A ban and no applicable telehealth pathway.

    Rx required
    No
    Telehealth
    N/A

Frequently asked questions

What is Humanin?

This mitochondrial peptide is investigated for neuronal protection, cell survival and metabolism; circulating concentrations decrease with age.

Which applications are being investigated?

Investigations focus on energy metabolism, metabolic health, longevity markers. The indication ratings summarize proposed applications and do not establish a study design or an approved treatment. Discuss any intended use with a qualified clinician.

Which dosing schedules are discussed?

Human doses have not been established. Injectable use belongs to research settings, and the approximate half-life is estimated at 3 hours. Community protocols name a low starting amount and titration for the standard dose; neither includes a numeric amount. Frequency depends on the protocol and the route varies. Obtain qualified clinical advice rather than converting these descriptions into a human dose.

What should I know about adverse effects?

Adverse reactions can differ with the amount administered, the route and individual sensitivity. Human studies do not fully characterize the compound-specific adverse-effect profile. Watch for local injection reactions and possible allergy, and discuss symptoms with a qualified clinician.

References

  1. Hashimoto Y et al. — Humanin discovery (PNAS 2001) (2001)

  2. Humanin: a novel mitochondrial-derived peptide that protects against cellular stress (2003)

  3. Humanin and the mitochondria in Alzheimer disease (2015)

  4. Humanin: A mitochondrial-derived peptide in the treatment of apoptosis-related diseases. (2021)

    PMID 33130077DOI 10.1016/j.lfs.2020.118679

  5. Role of humanin, a mitochondrial-derived peptide, in cardiovascular disorders. (2020)

    PMID 32680738DOI 10.1016/j.acvd.2020.03.020